Theragnostics combines diagnostic imaging with radionuclide therapy, allowing healthcare professionals to both diagnose and treat cancer in a highly targeted manner. This approach uses radiopharmaceuticals that target application specific cancer cells to provide personalized treatment while minimizing damage to healthy tissues.

The RATIONALE network (COST Action Ca22118) is a European initiative that fosters collaboration between experts involved in radionuclide theragnostics. The project focuses on optimizing theragnostic procedures, standardizing dosimetry, and facilitating the clinical translation of theragnostic research into personalized cancer treatments. Further, RATIONALE sets a strong focus on enhancing theranostic education in Europe and beyond.

Theragnostics is primarily used for treating of thyroid cancer, neuroendocrine tumors and prostate cancer. Ongoing research aims to expand its use to other cancer types, including some that are currently under investigation in clinical trials.

Dosimetry means the assessment of the amount of radiation absorbed by the tumor and healthy tissues, allowing for personalized treatment plans that maximize effectiveness and minimize side effects. Standardizing dosimetry and enhancing its accessibility across theragnostic centers is a key goal of the RATIONALE project.

Healthcare professionals, researchers, industry experts and other persons involved in theragnostics can participate in the RATIONALE project by joining working groups, attending training events, or applying for grants. The project aims to advance theragnostics research and clinical applications through collaboration across Europe and beyond.